Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $4.80K | $124K | $166K | $165K | $87.8K | $88.6K | $9.00K | $11.0K | $6.00K |
| Revenue growth | — | — | 2491.7% | 33.0% | -0.6% | -46.7% | 1.0% | -89.8% | 22.2% | -45.5% |
| Gross profit | $0.00 | -$3.20K | $54.0K | $120K | $114K | $39.8K | $60.1K | $5.40K | $6.60K | $3.81K |
| Gross margin | — | -66.7% | 43.4% | 72.5% | 69.2% | 45.4% | 67.8% | 60.0% | 60.0% | 63.4% |
| Operating income | -$760K | -$1.18M | -$1.11M | -$1.13M | -$1.11M | -$3.13M | -$10.2M | -$5.62M | -$5.74M | -$6.14M |
| Operating margin | — | -24537.6% | -895.7% | -682.9% | -677.7% | -3562.2% | -11562.5% | -62445.9% | -52216.9% | -102380.2% |
| Net income | -$766K | -$2.66M | -$13.7M | -$8.48M | -$36.3M | $19.2M | -$10.1M | -$5.29M | -$5.49M | -$6.00M |
| Net margin | — | -55398.1% | -10977.2% | -5126.1% | -22082.2% | 21892.8% | -11449.3% | -58739.7% | -49940.7% | -99916.8% |
| EPS (diluted) | -$0.01 | -$0.03 | -$3.50 | -$0.82 | -$62.69 | $5.61 | -$0.93 | -$3.76 | -$3.71 | -$2.52 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$445K | -$890K | -$1.05M | -$1.21M | -$435K | -$2.22M | -$7.80M | -$8.03M | -$5.30M | -$5.86M |
| Share buybacks | — | — | — | — | — | — | $0.00 | $271K | $175K | $10.0K |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $222K | $13.7K | $304K | $88.6K | $98.0K | $10.7M | $8.32M | $3.47M | $5.94M | $7.21M |
| Total assets | $323K | $203K | $477K | $531K | $718K | $11.3M | $19.2M | $10.7M | $6.67M | $7.81M |
| Total liabilities | $480K | $2.44M | $4.47M | $8.60M | $40.5M | $1.05M | $3.32M | $371K | $328K | $285K |
| Long-term debt | — | $493K | — | — | — | — | — | — | — | — |
| Shareholders' equity | -$158K | -$2.24M | -$3.99M | -$8.07M | -$39.8M | $10.2M | $15.9M | $10.3M | $6.34M | $7.51M |
| Retained earnings | -$767K | -$3.43M | -$17.1M | -$25.6M | -$61.9M | -$43.7M | -$53.8M | -$59.1M | -$64.6M | -$70.6M |
| Shares (wtd avg diluted) | 105M | 115M | 6.02M | 22.5M | 1.54M | 3.25M | 10.9M | 1.41M | 1.48M | 2.38M |
Every figure is extracted from CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.